Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?
作者信息
Biemans Vince Bc, Verstockt Bram
机构信息
Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastrict, The Netherlands.
出版信息
United European Gastroenterol J. 2020 Aug;8(7):753-754. doi: 10.1177/2050640620942641. Epub 2020 Jul 8.
Abstract
摘要
相似文献
1
Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?托法替布，溃疡性结肠炎和克罗恩病中的双面杰纳斯？
United European Gastroenterol J. 2020 Aug;8(7):753-754. doi: 10.1177/2050640620942641. Epub 2020 Jul 8.
2
Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.在中重度溃疡性结肠炎中评估托法替布疗效的暴露-反应特征：一项剂量范围的 2 期试验结果。
Br J Clin Pharmacol. 2018 Jun;84(6):1136-1145. doi: 10.1111/bcp.13523. Epub 2018 Mar 23.
3
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.真实世界中在三级中心使用托法替布治疗炎症性肠病的经验。
Dig Dis Sci. 2019 Jul;64(7):1945-1951. doi: 10.1007/s10620-019-05492-y. Epub 2019 Feb 7.
4
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.托法替布治疗溃疡性结肠炎：溃疡性结肠炎临床项目的感染率分析。
J Crohns Colitis. 2021 Jun 22;15(6):914-929. doi: 10.1093/ecco-jcc/jjaa233.
5
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.他卡西醇治疗中重度溃疡性结肠炎的真实世界疗效：一项英国多中心经验。
J Crohns Colitis. 2020 Oct 5;14(10):1385-1393. doi: 10.1093/ecco-jcc/jjaa075.
6
Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.与每日两次 5mg 和 10mg 托法替尼（Janus 激酶抑制剂）治疗自身免疫性疾病相关的药物不良反应：系统评价和随机对照试验的荟萃分析。
Clin Rheumatol. 2019 Feb;38(2):523-534. doi: 10.1007/s10067-018-4299-4. Epub 2018 Sep 22.
7
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.在健康受试者和类风湿关节炎、克罗恩病、溃疡性结肠炎或特应性皮炎受试者中的乌帕替尼药代动力学：I 期和 II 期临床试验的群体分析。
J Clin Pharmacol. 2020 Apr;60(4):528-539. doi: 10.1002/jcph.1550. Epub 2019 Nov 7.
8
Pharmacology and safety of tofacitinib in ulcerative colitis.托法替布治疗溃疡性结肠炎的药理学和安全性。
Gastroenterol Hepatol. 2021 Jan;44(1):39-48. doi: 10.1016/j.gastrohep.2020.04.012. Epub 2020 Aug 20.
9
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.托法替布，一种口服 Janus 激酶抑制剂：在溃疡性结肠炎临床项目中对恶性肿瘤（不包括非黑色素瘤皮肤癌）事件的分析。
Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199.
10
Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.Janus 激酶抑制剂：溃疡性结肠炎的一种新口服治疗选择。
J Clin Gastroenterol. 2019 Oct;53(9):635-640. doi: 10.1097/MCG.0000000000001250.
本文引用的文献
1
Is tofacitinib a game-changing drug for ulcerative colitis?托法替布是否为溃疡性结肠炎带来变革性药物？
United European Gastroenterol J. 2020 Aug;8(7):755-763. doi: 10.1177/2050640620935732. Epub 2020 Jun 18.
2
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.托法替尼治疗溃疡性结肠炎：前瞻性荷兰克罗恩病和结肠炎倡议（ICC）注册研究结果。
Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1.
3
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.JAK-STAT 通路靶向治疗炎症性肠病。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19.
4
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.中重度活动型溃疡性结肠炎患者的一线和二线药物治疗：一项更新的网络荟萃分析。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13.
5
New biologics and small molecules in inflammatory bowel disease: an update.炎症性肠病中的新型生物制剂和小分子药物：最新进展
Therap Adv Gastroenterol. 2019 May 26;12:1756284819853208. doi: 10.1177/1756284819853208. eCollection 2019.
6
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.4 例急性重度溃疡性结肠炎患者应用高强度托法替布诱导治疗的疗效。
Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1. doi: 10.1016/j.cgh.2018.11.022. Epub 2018 Nov 17.
7
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（细胞内信号通路：酪氨酸激酶和 mTOR 抑制剂）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16.
8
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.托法替布治疗溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
9
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.托法替布用于克罗恩病的诱导和维持治疗：两项IIb期随机安慰剂对照试验的结果
Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.
Zotero 插件